A Multicentre Study of Pathological Complete Response in HER2-positive Early Breast Cancer Treated with Neoadjuvant Pertuzumab and Trastuzumab. Issue 7 (July 2019) - Chambers, J.; Maxwell, A.; Kingdon, S.